Clinical Trials
112 trialsProton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
NRG Oncology
TEMOBIC
Assistance Publique Hopitaux De Marseille
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Washington University School of Medicine
PRC
The Cooper Health System
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Abramson Cancer Center at Penn Medicine
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
M.D. Anderson Cancer Center
FIGHT-209
Incyte Corporation
CBT-I in PBT
Virginia Commonwealth University
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
Memorial Sloan Kettering Cancer Center
OU-SCC-PI-4G
University of Oklahoma
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Grupo Español de Investigación en Neurooncología
Abemaciclib in Patients with Oligodendroglioma
Abramson Cancer Center at Penn Medicine
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
Washington University School of Medicine
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
Radiation Therapy Oncology Group
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Novartis
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
KING
Karyopharm Therapeutics Inc
Everolimus With and Without Temozolomide in Adult Low Grade Glioma
University of California, San Francisco
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma
Henan Provincial People's Hospital
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
National Cancer Institute (NCI)
Antineoplaston Therapy in Treating Children With Brain Tumors
Burzynski Research Institute
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
Wake Forest University Health Sciences
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor
Wake Forest University Health Sciences
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
Wake Forest University Health Sciences
Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Jonsson Comprehensive Cancer Center
Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas
Radiation Therapy Oncology Group
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
University of California, San Francisco
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
University of California, Davis
Topotecan in Treating Patients With Recurrent Brain Tumors
Canadian Cancer Trials Group
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
Northwestern University
Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases
Northwestern University
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
Medical College of Wisconsin
Radiation Therapy in Treating Young Patients With Gliomas
Children's Oncology Group
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
Case Comprehensive Cancer Center
TAVAREC
European Organisation for Research and Treatment of Cancer - EORTC
A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas
Huashan Hospital
Temozolomide in Treating Patients With Low-Grade Glioma
University of California, San Francisco
Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma
The Cleveland Clinic
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
National Cancer Institute (NCI)
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Pediatric Brain Tumor Consortium
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma
Burzynski Research Institute
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
University of California, San Francisco
Trial of IDH305 in IDH1 Mutant Grade II or III Glioma
NYU Langone Health